Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年半年度报告' which translates to '2023 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, financial indicators, and other comprehensive content typical of an interim or quarterly report. The report covers the period January to June 2023, includes financial statements, management analysis, and risk disclosures. It is not a brief announcement or a certification letter but a full report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
第四届董事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Lingkang Pharmaceutical Group Co., Ltd. It details the convening and decisions of the fourth board's ninth meeting, including approval of the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report being published on the Shanghai Stock Exchange website, indicating this document is an announcement of board decisions rather than the reports themselves. The document length is short (739 characters), and it does not contain the actual financial data or detailed report content. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K), but rather a Regulatory Filing (RNS) announcing board resolutions and referencing other reports.
2023-08-25 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report on the official website. The document length is 2390 characters, which is relatively short and suggests it is a summary rather than a full report. However, it contains substantive financial data and analysis for the half-year period, which aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a certification, but includes key financial figures and shareholder data for the half-year period. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
关于子公司盐酸艾司洛尔注射液通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding its subsidiary's drug product passing a generic drug consistency evaluation by the National Medical Products Administration of China. It details the drug's approval, regulatory references, and potential market impact. The document is short (1515 characters) and serves as a regulatory announcement about a product approval and related information. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not a voting result, board change, or capital update. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and compliance with regulatory standards, which does not fit other specific categories.
2023-08-15 Chinese
关于子公司获得注射用拉氧头孢钠注册批件的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding its subsidiary obtaining drug registration certificates for a pharmaceutical product from the National Medical Products Administration of China. It details the drug's specifications, approval numbers, and regulatory compliance. The document is a formal announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is about 2350 characters, which is relatively short and focused on a specific regulatory approval. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-08-03 Chinese
东方金诚国际信用评估有限公司关于灵康药业集团股份有限公司2023年半年度业绩预告及实控人拟减持公司股份的关注公告
Regulatory Filings Classification · 95% confidence The document is a credit rating agency announcement by 东方金诚国际信用评估有限公司 regarding the 2023 half-year performance forecast of 灵康药业集团股份有限公司 and the planned share reduction by a controlling shareholder. It includes a summary of the company's expected financial results for the half-year period and details about the shareholder's planned share sale. The document is short (1484 characters) and serves as a notice or announcement rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR). It also does not fit into other categories such as Earnings Release or Capital/Financing Update. Given the nature of the content and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-01 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.